Format

Send to

Choose Destination
Future Oncol. 2019 Aug;15(23):2733-2741. doi: 10.2217/fon-2019-0160. Epub 2019 Jul 15.

Use of subcutaneous and intravenous trastuzumab: real-world experience from three hospitals in Sweden.

Author information

1
Department of Oncology, Faculty of Medicine & Health, Örebro University, SE 70182 Örebro, Sweden.
2
Breast Unit, Department of Surgery, Kalmar County Hospital, Kalmar, Sweden.
3
Department of Oncology, Sundsvall County Hospital, Sundsvall, Sweden.
4
Real World & Analytic Solutions (RWAS), IQVIA, Stockholm, Sweden.
5
PHC Data Science, F Hoffmann-La Roche Ltd, Basel, Switzerland.

Abstract

Aim: We aimed to describe the use of subcutaneous (sc.) trastuzumab use in a real-world setting. Patients & methods: This retrospective cohort study evaluated electronic medical records of patients with early breast cancer and trastuzumab use from January 2010 to February 2018 in three hospitals in Sweden. Results: In total, 363 patients received trastuzumab during study period. Of these, 217 (59.8%) patients started treatment with sc. trastuzumab and 146 (40.2%) with intravenous trastuzumab. After sc. trastuzumab approval, use of sc. trastuzumab increased from 70.2% in 2014 to 100% in 2017. Since 2013, 34 of 35 (97.4%) patients who started with intravenous trastuzumab switched to sc. formulation. Conclusion: Trastuzumab sc. quickly became the prevailing formulation for treatment in HER2-positive early breast cancer.

KEYWORDS:

HER2-positive; breast cancer; real-world setting; subcutaneous; trastuzumab

PMID:
31306041
DOI:
10.2217/fon-2019-0160

Supplemental Content

Full text links

Icon for Atypon
Loading ...
Support Center